Comparison of propranolol and LB 46 (prinodolol) on hyperthyroid tachycardia

A. G. ARBAB
B.Sc., M.B., B.S.

P. TURNER
M.D., B.Sc., M.R.C.P.

Division of Clinical Pharmacology,
Medical Professorial Unit,
St Bartholomew’s Hospital, London, E.C.1

Summary

LB 46 (prinodolol) a β-adrenergic receptor blocking drug which is more potent than propranolol in euthyroid subjects, is less effective in inhibiting hyperthyroid tachycardia. This is probably due to its intrinsic sympathomimetic activity.

Cardiovascular symptoms in hyperthyroidism are due in part to increased responsiveness to adrenergic stimulation (Turner, 1970; Turner & Hill, 1968; Leak, 1970). The observation that the adrenergic neurone blocking drugs, reserpine and guanethidine reduce many of the symptoms of experimental and spontaneous hyperthyroidism suggested that adrenergic mechanisms are important in the production of most of the peripheral cardiovascular manifestations of this condition (Canary et al., 1959; Gaffney, Braunwald & Kahler, 1961; Goldstein & Killip, 1965).

Propranolol, a β-adrenoceptor blocking agent, in addition to its therapeutic effect on cardiac arrhythmias due to other causes, has been shown effectively to control tachycardia in hyperthyroidism (Turner, Granville-Grossman & Smart, 1965; Parsons & Hewitt, 1967; Rowlands, Howitt & Markham, 1965).

Another β-blocking drug, LB 46 (prinodolol) reduces isoprenaline and exercise-induced tachycardia in much smaller doses than propranolol but possesses intrinsic sympathomimetic activity (Hill & Turner, 1968; Frick, Heikkila & Luomanmäki, 1970).

In this paper, an attempt was made to compare the β-blocking effects of LB 46 and propranolol on hyperthyroid tachycardia.

Method

Eight in-patients, one male and seven females, between 27 and 60 years of age, were selected, having all the characteristic signs and symptoms of hyperthyroidism and with confirmatory laboratory data. All were in sinus rhythm. They were given propranolol 5 and 10 mg, LB 46 0-5 and 1-0 mg or normal saline intravenously, under double blind conditions at the same time of day over 5 days. The order of administration of drugs was randomized but smaller doses were always given before the larger.

Patients were lying comfortably in bed, while their resting heart rates were recorded with a Cambridge direct writing electrocardiograph for 5 min at 1 min intervals. Immediately after taking the last record of heart rate, the drug was injected intravenously slowly over a period of 1½ min. At the end of the injection and subsequently after each minute for 5 min and finally at the end of the tenth min, heart rates were recorded as above. This procedure was followed on each of the 5 days with each patient. The data were analysed using Student’s ‘t’ test for comparison.

Results

The results were analysed in two ways, namely using the final heart rates at the tenth min after injection and secondly, the fall in heart rates from mean pretreatment values to that of the tenth min post injection. The mean values are shown in Table 1. Statistical analysis (Tables 2 and 3) showed that both propranolol and LB 46 produced a significant fall in heart rate when compared with normal saline, but that propranolol was significantly more effective than both doses of LB 46.

When the final heart rates were considered, those after propranolol were significantly lower than those after normal saline, while those after LB 46 were not significantly different (0-5 mg) or only marginally so (1-0 mg).

Discussion

LB 46 is a more potent β-adrenergic receptor blocking drug than propranolol. In animal experiments, ratios varying between ten and forty times that of propranolol have been given (Giudicelli, Schmitt & Boissier, 1969; Saameli, 1967) while in normal human volunteers Hill & Turner (1969) found it to be between twenty and forty times more...
A. G. Arbab and P. Turner

Table 1. The mean final heart rates (beats/min ± SE) at the tenth min after injection, and the mean falls in heart rate (beats/min ± SE) after administration of LB 46, propranolol and normal saline

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mean final heart rate</th>
<th>SE</th>
<th>Mean fall in heart rate</th>
<th>SE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline</td>
<td>94·5 ± 3·2</td>
<td>3·6</td>
<td>± 1·65</td>
<td></td>
</tr>
<tr>
<td>LB 46 0·5 mg</td>
<td>90·2 ± 4·8</td>
<td>13·6</td>
<td>± 1·88</td>
<td></td>
</tr>
<tr>
<td>LB 46 1·0 mg</td>
<td>88·9 ± 3·51</td>
<td>12·9</td>
<td>± 4·77</td>
<td></td>
</tr>
<tr>
<td>Propranolol 5 mg</td>
<td>83·1 ± 1·74</td>
<td>22·7</td>
<td>± 3·56</td>
<td></td>
</tr>
<tr>
<td>Propranolol 10 mg</td>
<td>83·9 ± 2·04</td>
<td>19·0</td>
<td>± 2·07</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Comparison of the mean falls in heart rate of hyperthyroid patients after LB 46, propranolol and normal saline

<table>
<thead>
<tr>
<th>Treatment</th>
<th>d</th>
<th>SE</th>
<th>t</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline v propranolol 5 mg</td>
<td>19·1</td>
<td>± 3·7</td>
<td>5·16</td>
<td>&lt;0·01</td>
</tr>
<tr>
<td>Normal saline v propranolol 10 mg</td>
<td>15·4</td>
<td>± 2·38</td>
<td>6·47</td>
<td>&lt;0·01</td>
</tr>
<tr>
<td>Normal saline v LB 46 0·5 mg</td>
<td>10·0</td>
<td>± 3·27</td>
<td>3·06</td>
<td>&lt;0·02</td>
</tr>
<tr>
<td>Normal saline v LB 46 1·0 mg</td>
<td>9·3</td>
<td>± 3·79</td>
<td>2·44</td>
<td>&lt;0·05</td>
</tr>
<tr>
<td>Propranolol 5 mg v LB 46 0·5 mg</td>
<td>9·1</td>
<td>± 4·37</td>
<td>2·08</td>
<td>&lt;0·1</td>
</tr>
<tr>
<td>Propranolol 5 mg v LB 46 1·0 mg</td>
<td>9·8</td>
<td>± 3·84</td>
<td>2·57</td>
<td>&lt;0·05</td>
</tr>
<tr>
<td>Propranolol 10 mg v LB 46 1·0 mg</td>
<td>6·1</td>
<td>± 3·19</td>
<td>1·91</td>
<td>&lt;0·1</td>
</tr>
</tbody>
</table>

Table 3. Comparison of the mean final heart rates of hyperthyroid patients after LB 46, propranolol and normal saline

<table>
<thead>
<tr>
<th>Treatment</th>
<th>d</th>
<th>SE</th>
<th>t</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline v propranolol 5 mg</td>
<td>11·4</td>
<td>± 3·2</td>
<td>3·56</td>
<td>&lt;0·01</td>
</tr>
<tr>
<td>Normal saline v propranolol 10 mg</td>
<td>10·6</td>
<td>± 2·88</td>
<td>3·64</td>
<td>&lt;0·01</td>
</tr>
<tr>
<td>Normal saline v LB 46 0·5 mg</td>
<td>4·3</td>
<td>± 4·1</td>
<td>1·05</td>
<td>NS</td>
</tr>
<tr>
<td>Normal saline v LB 46 1·0 mg</td>
<td>5·6</td>
<td>± 2·42</td>
<td>2·31</td>
<td>0·05</td>
</tr>
<tr>
<td>Propranolol 5 mg v LB 46 0·5 mg</td>
<td>7·1</td>
<td>± 5·15</td>
<td>1·38</td>
<td>NS</td>
</tr>
<tr>
<td>Propranolol 10 mg v LB 46 1·0 mg</td>
<td>5·0</td>
<td>± 2·78</td>
<td>1·8</td>
<td>NS</td>
</tr>
</tbody>
</table>

effective in inhibiting isoprenaline and exercise-induced tachycardia when given orally.

Preliminary intravenous studies with hyperthyroid patients suggested that a ratio of 10 was more likely to apply and for this reason 0·5 and 1·0 mg LB 46 were compared with 5 and 10 mg of propranolol in this definitive study. However, in this study although both LB 46 and propranolol significantly reduced hyperthyroid tachycardia, propranolol was significantly more effective than LB 46.

More recent normal volunteer studies (Arbab & Turner, unpublished observations) show that 0·25 mg LB 46 inhibited isoprenaline-induced tachycardia to a similar extent as propranolol 5 mg when given intravenously, and 0·5 mg was markedly more effective, so that in terms of β-receptor blockade both 0·5 and 1·0 mg may be considered supramaximal.

These results are in accord with those obtained with other β-receptor blocking drugs including oxprenolol, practolol (Turner & Hill, 1968) and alprenolol (Turner, 1970) which indicate that compounds possessing intrinsic sympathomimetic activity are inferior in the control of hyperthyroid tachycardia to those such as propranolol and sotalol (Ekue, Lowe & Shanks, 1970), which do not.

It is probable that the increased responsiveness to adrenergic stimulation seen in hyperthyroidism and the increased intrinsic activity of the tissues in this condition may be explained in terms of increased adenyl cyclase in the tissues with a consequent rise in cyclic AMP (Robison, Butcher & Sutherland, 1967).

Acknowledgments

We thank the physicians of St Bartholomew's Hospital for allowing us to study their patients, the staff who cooperated with us and Sandoz Products Ltd and ICI Ltd who kindly provided LB 46 and propranolol respectively. A.G.A. is supported by a Colombo Plan Scholarship.

References


Propranolol and LB 46 for hyperthyroid tachycardia


Comparison of propranolol and LB 46 (prinodolol) on hyperthyroid tachycardia
A. G. Arbab and P. Turner

Postgrad Med J 1971 47: 329-331
doi: 10.1136/pgmj.47.548.329

Updated information and services can be found at:
http://pmj.bmj.com/content/47/548/329

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/